Actively Recruiting
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2024-08-06
102
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
Sponsors
C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
To further validate the performance of the high-sensitivity MRD assay in patients with squamous esophageal cancer who have completed radical radiotherapy; to validate whether MRD-negative patients can maintain a good prognosis under regular follow-up; and to validate whether MRD-positive patients can improve their survival with consolidation therapy with PD-1 monotherapy.
CONDITIONS
Official Title
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Histologically or cytologically confirmed squamous cell carcinoma of esophageal cancer, clinical stage I-VIa, primary unresectable
- ECOG performance status 0 or 1
- Normal routine blood tests and liver/kidney function
- Completed radical radiotherapy with 50-60 Gy dose
- Received systemic platinum-based chemotherapy combined with paclitaxel or 5-FU, with or without PD-1 monotherapy, or S-1 monotherapy for elderly patients
- Provided informed consent
You will not qualify if you...
- History of cancers other than hypopharyngeal carcinoma in situ, non-malignant skin cancer, or cervical carcinoma in situ
- Current active infections or serious illnesses like myocardial infarction within 6 months
- History of autoimmune diseases
- Participation in other clinical trials currently or within 4 weeks prior
- Received more than 4 cycles of systemic chemotherapy alone or combined with immunotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer hospital, CAMS
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here